Autophagy-Lysosome Dysfunction in Cancer: Molecular Mechanism and Therapeutic Prospects

The autophagy-lysosomal pathway constitutes a fundamental intracellular degradation system that recycles cellular components and eliminates damaged organelles through both non-selective and selective mechanisms. Selective autophagy is mediated by specific receptors that target substrates for degradation, including mitochondria (mitophagy), the endoplasmic reticulum (ER-phagy), lipid droplets (lipophagy), and intracellular pathogens (xenophagy), collectively forming a network that maintains cellular homeostasis. In tumors, autophagy-lysosomal dysfunction plays a dual role: on the one hand, it suppresses malignant transformation during early tumorigenesis by maintaining genomic stability and limiting oxidative stress; on the other hand, it drives the progression of established tumors by enhancing metabolic adaptation, promoting therapeutic resistance and facilitating immune evasion. This functional shift is driven by metabolic reprogramming within the tumor microenvironment, ferroptosis inhibition, inflammasome activation and spatiotemporal heterogeneity. Recent therapeutic strategies have evolved from broad-spectrum inhibitors toward precision interventions, including nanodrug delivery systems, patient stratification guided by single-cell and spatial multi-omics and targeted protein degradation. Technologies such as proteolysis-targeting chimeras and lysosome-targeting chimeras offer promising approaches for selectively modulating protein degradation pathways. The integration of these approaches with immune checkpoint blockade and epigenetic modulators has opened new avenues for overcoming drug resistance and improving clinical outcomes. This review systematically explores the molecular mechanisms, dual functions and therapeutic implications of autophagy-lysosomal dysfunction in cancer, emphasizing the shift from non-selective inhibition toward selective precision targeting.

Authors

Institutions

Publication Details

Journal
Theoretical and Natural Science
Published
2026-11-17
DOI
https://doi.org/10.54254/2753-8818/2026.39056
Primary Topic
Autophagy in Disease and Therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Autophagy-Lysosome Dysfunction in Cancer: Molecular Mechanism and Therapeutic Prospects

Yuming Lou
2 links
Theoretical and Natural Science
Autophagy in Disease and Therapy
article

Autophagy-Lysosome Dysfunction in Cancer: Molecular Mechanism and Therapeutic Prospects

Yuming Lou
article en

Abstract

The autophagy-lysosomal pathway constitutes a fundamental intracellular degradation system that recycles cellular components and eliminates damaged organelles through both non-selective and selective mechanisms. Selective autophagy is mediated by specific receptors that target substrates for degradation, including mitochondria (mitophagy), the endoplasmic reticulum (ER-phagy), lipid droplets (lipophagy), and intracellular pathogens (xenophagy), collectively forming a network that maintains cellular homeostasis. In tumors, autophagy-lysosomal dysfunction plays a dual role: on the one hand, it suppresses malignant transformation during early tumorigenesis by maintaining genomic stability and limiting oxidative stress; on the other hand, it drives the progression of established tumors by enhancing metabolic adaptation, promoting therapeutic resistance and facilitating immune evasion. This functional shift is driven by metabolic reprogramming within the tumor microenvironment, ferroptosis inhibition, inflammasome activation and spatiotemporal heterogeneity. Recent therapeutic strategies have evolved from broad-spectrum inhibitors toward precision interventions, including nanodrug delivery systems, patient stratification guided by single-cell and spatial multi-omics and targeted protein degradation. Technologies such as proteolysis-targeting chimeras and lysosome-targeting chimeras offer promising approaches for selectively modulating protein degradation pathways. The integration of these approaches with immune checkpoint blockade and epigenetic modulators has opened new avenues for overcoming drug resistance and improving clinical outcomes. This review systematically explores the molecular mechanisms, dual functions and therapeutic implications of autophagy-lysosomal dysfunction in cancer, emphasizing the shift from non-selective inhibition toward selective precision targeting.

Theoretical and Natural ScienceVol. 203(1)
Chongqing Medical University (CN)
Good health and well-being
Autophagy in Disease and Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon